PAVmed Subsidiary Lucid Diagnostics Announces Commercial Launch of EsoGuard Esophageal DNA Test
19 déc. 2019 09h30 HE
|
PAVmed Inc.
First commercially available DNA test designed to facilitate the diagnosis of Barrett’s Esophagus and related precursors to highly lethal form of esophageal cancer First patients to undergo testing...
PAVmed Provides Update on CarpX™ Clinical Safety Study
13 déc. 2019 09h30 HE
|
PAVmed Inc.
NEW YORK, Dec. 13, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today provided an update on...
PAVmed Reports Third Quarter 2019 Financial Results and Provides Business Update
21 nov. 2019 16h00 HE
|
PAVmed Inc.
Conference call to be held on November 21, 2019 at 4:30 p.m. Eastern time NEW YORK, Nov. 21, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly...
PAVmed Partners with Laser Technology Pioneer Dr. Jacob Wong to Develop and Commercialize Non-Invasive Laser-based Diagnostic Products
14 nov. 2019 09h30 HE
|
PAVmed Inc.
Secures exclusive worldwide license for Nondispersive Infrared (NDIR) laser technology Launches joint development program for NDIR laser-based diagnostic products to measure glucose, electrolytes...
PAVmed’s PortIO™ Intraosseous Infusion System Achieves Multiple Milestones
07 nov. 2019 09h30 HE
|
PAVmed Inc.
Unprecedented six-month maintenance-free implant duration achieved FDA pre-submission meeting date supporting de novo application secured Broad method and device patents granted by USPTO NEW YORK,...
PAVmed to Hold Business Update Conference Call on November 21, 2019
06 nov. 2019 09h30 HE
|
PAVmed Inc.
NEW YORK, Nov. 06, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the...
PAVmed Secures Financing up to $14 Million for Advancement of its Lead Products to Commercialization
05 nov. 2019 07h00 HE
|
PAVmed Inc.
Extends cash runway to support multiple milestones including commercialization of two lead products NEW YORK, Nov. 05, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or...
PAVmed Reports Second Quarter 2019 Financial Results and Provides Business Update
05 sept. 2019 09h30 HE
|
PAVmed Inc.
Conference call to be held on September 5, 2019 at 4:30 p.m. Eastern time NEW YORK, Sept. 05, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly...
USPTO Grants PAVmed Patent Covering its CarpX™ Device
21 août 2019 09h30 HE
|
PAVmed Inc.
NEW YORK, Aug. 21, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the U.S....
PAVmed Successfully Completes Clinical Safety Study Procedures for CarpX™ 510(k) Re-submission
15 août 2019 09h30 HE
|
PAVmed Inc.
All 20 patients underwent successful CarpX procedures while passing primary effectiveness endpoint, with all follow-up patients to date passing primary safety endpoint NEW YORK, Aug. 15, 2019 ...